Form 4: Pacira BioSciences CEO Frank D. Lee Acquires 350,000 Shares of Common Stock
SEC Form 4 Filing
Frank D. Lee, CEO of Pacira BioSciences, acquired 350,000 shares of common stock on February 1, 2025, as part of a restricted stock unit grant.
Summary
- On February 1, 2025, Frank D. Lee, the CEO of Pacira BioSciences, acquired 350,000 shares of the company's common stock.
- This acquisition was in the form of restricted stock units (RSUs).
- The RSUs vest in four equal annual installments starting on February 1, 2026, contingent upon Lee's continued service with Pacira BioSciences.
- Each RSU represents the right to receive one share of Pacira BioSciences' common stock.
- Following the transaction, Lee directly owns 448,409 shares of Pacira BioSciences' common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The CEO's acquisition of shares suggests confidence in the company, but it's a routine transaction related to compensation.
Positives
- The CEO's acquisition of a significant number of shares could be interpreted as a positive signal about his confidence in the company's future prospects.
Future Outlook
The vesting of the restricted stock units is contingent upon the reporting person's continued service with the issuer.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's acquisition of shares, which is a common form of executive compensation.
Stakeholder Impact
- Shareholders may view the CEO's stock acquisition as a positive sign of alignment with their interests.
- Employees may see this as a sign of stability and confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | Date of transaction: CEO Frank D. Lee acquired 350,000 shares of common stock in the form of restricted stock units. |
| 02/01/2026 | First vesting date for the restricted stock units, with vesting occurring in four equal annual installments. |
| 02/04/2025 | Date of signature for the Form 4 filing. |
Keywords
Pacira BioSciences, Frank D. Lee, CEO, Form 4, Stock Acquisition, Restricted Stock Units, PCRX, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.